Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis

HIV preexposure prophylaxis (PrEP) is a key component of the Ending the HIV Epidemic (EHE) Initiative to curb new HIV diagnoses. In October 2019, emtricitabine/tenofovir alafenamide was added as an approved formulation for PrEP in addition to emtricitabine/tenofovir disoproxil fumarate; despite avai...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA network open 2023-11, Vol.6 (11), p.e2342781
Hauptverfasser:	McManus, Kathleen A, Fuller, Benjamin, Killelea, Amy, Strumpf, Andrew, Powers, Samuel D, Rogawski McQuade, Elizabeth T
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-HIV Agents - therapeutic use Cross-Sectional Studies Disease prevention Emtricitabine - therapeutic use Health Policy HIV Infections - drug therapy HIV Infections - prevention & control Humans Online Only Original Investigation Patient Protection & Affordable Care Act 2010-US Patient Protection and Affordable Care Act Patient safety Prior Authorization Tenofovir - therapeutic use United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!